GROWTH HORMONE AXIS / MATRIX
Three Compounds, One Axis, Different Evidence
How a long-acting GHRH analog, a two-receptor stack, and an FDA-approved comparator line up on mechanism, evidence, and regulatory status.
The short version
This page lines up CJC-1295, CJC-1295 / Ipamorelin, and tesamorelin on the dimensions that matter for reading GH-axis peptide research: mechanism, evidence base, administration, regulatory status, and the single biggest caution for each.
The short answer: all three aim at the same GH/IGF-1 axis, through overlapping but distinct receptor paths. Only tesamorelin has cleared FDA approval, and only for one narrow HIV-specific indication. CJC-1295 and CJC-1295 / Ipamorelin remain research chemicals with no approved use and, in the case of the combination, no trial of the combination itself. None of this is medical advice, and no dose is recommended anywhere on this page.
The comparison matrix
| Dimension | CJC-1295 | CJC-1295 / Ipamorelin | Tesamorelin |
|---|---|---|---|
| Mechanism | GHRH receptor agonist (long-acting analog) | GHRH receptor agonist + GHS-R1a (ghrelin receptor) agonist | GHRH receptor agonist (daily-dosed analog) |
| Most studied for | GH/IGF-1 elevation, receptor pharmacology | GH/IGF-1 elevation via dual-receptor stimulation (component data only) | Visceral and hepatic fat reduction in HIV-associated lipodystrophy |
| Evidence base | Early-phase human pharmacology (n=11-13); no trial of DAC/no-DAC use as body-composition therapy [3][4][5] | No trial of the fixed combination; inferred from separate CJC-1295 and ipamorelin data plus receptor cross-talk work [4][7][8][9] | Multiple Phase 3 trials and a 2026 five-trial meta-analysis; FDA-approved indication [6][11][13][14] |
| Administration studied | Subcutaneous injection, single and multi-dose | Subcutaneous injection, both components | Once-daily subcutaneous injection |
| Regulatory status | Not approved anywhere; research chemical | Not approved anywhere; research chemical (fixed blend never trialed) | FDA-approved (2010) for one HIV-specific indication only |
| Key caution | No large or long-term human trial exists [4] | Fixed blend untested; components have mismatched pharmacokinetics [4][8][9] | Visceral fat returns after stopping; long-term oncologic data limited [13] |
Mechanism
CJC-1295 and tesamorelin are both GHRH-receptor agonists — the same target, different molecules. CJC-1295's DAC variant adds an albumin-binding arm for a multi-day action; tesamorelin instead relies on DPP-IV resistance alone and is dosed daily. CJC-1295 / Ipamorelin adds a second receptor to the CJC-1295 half: ipamorelin activates GHS-R1a, the ghrelin receptor, through a separate calcium-signaling path. A cell-based study found co-activating both receptor types roughly doubled the cAMP response versus the GHRH receptor alone [9] — the mechanistic case for combining them, though that finding comes from cloned receptors in a dish, not from a trial of the paired compounds in people.
Evidence base
This is where the three separate cleanly. Tesamorelin has the deepest record: multiple Phase 3 trials in defined HIV populations, a 2026 meta-analysis across five RCTs, and a favorable liver-safety rating from a federal drug-safety reference [6][10][11][13][14]. CJC-1295's human data are early-phase and small — dose-ranging pharmacology in a few dozen healthy adults, not body-composition outcome trials [3][4][5]. CJC-1295 / Ipamorelin has no trial of its own; every claim about the combination is inferred from the two components studied separately, plus in vitro receptor work [7][9]. Reading the evidence base honestly means treating these as three very different confidence levels, not three interchangeable options along a spectrum.
Administration studied
All three are studied as subcutaneous injections. CJC-1295's DAC form supports infrequent dosing because of its albumin-binding half-life; the no-DAC form clears in minutes to hours and would need much more frequent dosing to sustain an effect. Ipamorelin, similarly short-acting, is generally paired with a longer-acting GHRH partner for that reason. Tesamorelin is dosed once daily in its studied and approved form — a materially higher dosing burden than the long-acting alternatives, traded for a documented trial record.
Regulatory and approval status
Tesamorelin is the only FDA-approved compound on this desk — approved in 2010, for one narrow indication: reducing excess visceral fat in HIV-infected adults with lipodystrophy. It has no approval for general weight management, athletic use, or anti-aging use. CJC-1295 and ipamorelin are not approved for any human indication, in the United States or elsewhere; both have been reviewed for federal compounding bulk-substances lists without being recommended, with immunogenicity among the cited concerns. All three compounds are prohibited in sport at all times under WADA's peptide-hormone category.
Key caution
For CJC-1295, the defining caution is evidentiary: no large or long-term human trial exists, so its safety profile beyond a few weeks in a few dozen people is simply unknown [4]. For CJC-1295 / Ipamorelin, it is the mismatch between a well-characterized long-acting half and a short-acting, unstudied combination — everything about the stack is extrapolated, not measured [4][8][9]. For tesamorelin, the caution is different in kind: it is an approved drug with a real trial record, but that record covers one population (HIV-associated lipodystrophy) and one endpoint (visceral and hepatic fat); using it outside that population and indication moves back into the same uncharted territory the other two compounds already occupy [13].